Clinical Trial

A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) works in treating Endometrial Cancer (EC) compared to standard of care. The study also assesses whether Mo-Rez is safe and tolerated well by participants in comparison to standard of care and will help provide a better understanding of the main side effects of the drugs.
Protocol Amendment History 3 changes
notable Trial sites expanded: 14 -> 18 locations 2026-07-16
critical Recruitment opened 2026-07-03
notable Trial sites expanded: 0 -> 14 locations 2026-07-03
Trial Details
NCT Number NCT07286331
Lead Sponsor GlaxoSmithKline
Collaborators: ENGOT, GOG, APGOT
Conditions Neoplasms, Endometrial
Enrollment 600 participants
Start Date 2026-06-04
Primary Completion 2028-02-29 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-15